Value of usefulness of diffuse optical spectroscopic imaging for monitoring efficacy of aingle agent bevacizumab followed by Paclitaxel in breast cancer patients

Value of usefulness of diffuse optical spectroscopic imaging for monitoring efficacy of aingle agent bevacizumab followed by Paclitaxel in breast cancer patients - Diffuse optical spectroscopic imaging for monitoring bevacizumab and paclitaxel for breast cancer patinets

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015837

Enrollment

Registered

2014-12-03

Start date

2012-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stage3/4 breast cancer patients

Interventions

Diffuse Optical Spectroscopy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patinets who get informed and consent on paper. Patient age 20 yo or more Invasive breast cancer is confirmed by pathology Patient with stage 3 or stage 4 HER2 negative breast cancer by IHC or FISH method (6)ECOG Performance Status01 at baseline

Exclusion criteria

Exclusion criteria: (1) Patients who did not get informed consents on paper (2) Patient whom doctor judges this treatment is suirtable for.

Design outcomes

Primary

Measure	Time frame
The early hemoglobin response to single-agent bevacizumab.	—

Countries

Japan

Contacts

Public ContactShigeto UEDA

Saitama International Medical Center Department of breast oncology

syueda@saitama-med.ac.jp81-42-984-4670

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026